Psoriatic Arthritis

Risankizumab is linked to significantly greater improvements in psoriatic arthritis signs and symptoms than placebo in patients with an inadequate response, or intolerance, to other drugs, according to a speaker at the EULAR 2021 Congress.

Upadacitinib maintains its efficacy over 56 weeks in patients with psoriatic arthritis who had a prior inadequate response to at least one biologic disease-modifying antirheumatic drug, according to data presented at the EULAR 2021 Virtual Congress.

Air pollution is a predictor of poor response to biological treatment in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, according to a poster session at the EULAR 2021 Congress.

Secukinumab yielded a significantly longer time to flare than placebo in pediatric patients with enthesitis-related arthritis and juvenile psoriatic arthritis, according to findings presented at the EULAR 2021 Congress.

Guselkumab 100 mg administered every 8 weeks results in “significantly higher” ACR20 response rates vs. placebo in patients with psoriatic arthritis who had an inadequate response to TNF inhibitors, according to data presented at the EULAR 2021 Virtual Congress.

Although a range of biologic options are available to clinicians treating psoriatic arthritis, it crucial to know which disease domains are involved as this will “dictate treatment,” according to a presenter at the Biologic Therapies Summit.

Fecal microbiota transplantation is safe in patients with psoriatic arthritis, according to data from the first preliminary, randomized trial of the procedure in immune-mediated arthritis.

Findings from the Live Yes! INSIGHTS survey from the Arthritis Foundation showed that out of some 40,000 patient responses, 100% reported experiencing some kind of pain within the last 7 days.

Studies that feature work participation as an outcome in patients with inflammatory arthritis should identify key contextual factors — such as job type or social security system — upfront, according to new “points to consider” from EULAR.

Treatment with guselkumab results in higher enthesitis resolutions rates at week 24, with maintenance of those higher rates through 1 year, in patients with psoriatic arthritis, according to data published in Rheumatology.